COLL — Collegium Pharmaceutical Income Statement
0.000.00%
- $1.05bn
- $1.36bn
- $566.77m
- 84
- 76
- 94
- 98
Annual income statement for Collegium Pharmaceutical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 297 | 310 | 277 | 464 | 567 |
Cost of Revenue | |||||
Gross Profit | 103 | 180 | 151 | 214 | 326 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 320 | 254 | 259 | 431 | 423 |
Operating Profit | -23.7 | 56.2 | 17.6 | 33.3 | 143 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -22.7 | 27.6 | -3.37 | -28.8 | 75.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -22.7 | 26.8 | 71.5 | -25 | 48.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -22.7 | 26.8 | 71.5 | -25 | 48.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -22.7 | 26.8 | 76.2 | -25 | 48.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.679 | 0.761 | 1.98 | -0.046 | 1.64 |